Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

A phase I safety and immunogenicity dose escalation trial of plague vaccine, Flagellin/F1/V, in healthy adult volunteers (DMID 08-0066).

Frey SE, Lottenbach K, Graham I, Anderson E, Bajwa K, May RC, Mizel SB, Graff A, Belshe RB.

Vaccine. 2017 Dec 4;35(48 Pt B):6759-6765. doi: 10.1016/j.vaccine.2017.09.070. Epub 2017 Oct 14.

PMID:
29037578
2.

Inclusion of Flagellin during Vaccination against Influenza Enhances Recall Responses in Nonhuman Primate Neonates.

Kim JR, Holbrook BC, Hayward SL, Blevins LK, Jorgensen MJ, Kock ND, De Paris K, D'Agostino RB Jr, Aycock ST, Mizel SB, Parks GD, Alexander-Miller MA.

J Virol. 2015 Jul;89(14):7291-303. doi: 10.1128/JVI.00549-15. Epub 2015 May 6.

3.

Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.

Clark KM, Johnson JB, Kock ND, Mizel SB, Parks GD.

Virology. 2011 Oct 25;419(2):97-106. doi: 10.1016/j.virol.2011.08.005. Epub 2011 Aug 31.

4.

Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88.

Bates JT, Graff AH, Phipps JP, Grayson JM, Mizel SB.

J Immunol. 2011 Jun 1;186(11):6255-62. doi: 10.4049/jimmunol.1001855. Epub 2011 Apr 22.

5.

Flagellin as an adjuvant: cellular mechanisms and potential.

Mizel SB, Bates JT.

J Immunol. 2010 Nov 15;185(10):5677-82. doi: 10.4049/jimmunol.1002156. Review.

6.

Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin.

Ahmed M, Puckett S, Arimilli S, Braxton CL, Mizel SB, Lyles DS.

J Virol. 2010 Nov;84(22):12093-8. doi: 10.1128/JVI.00406-10. Epub 2010 Sep 15.

7.

A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.

Delaney KN, Phipps JP, Johnson JB, Mizel SB.

Viral Immunol. 2010 Apr;23(2):201-10. doi: 10.1089/vim.2009.0107.

8.

Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Braxton CL, Puckett SH, Mizel SB, Lyles DS.

J Virol. 2010 Apr;84(7):3552-61. doi: 10.1128/JVI.01572-09. Epub 2010 Jan 20.

9.

Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.

Weimer ET, Ervin SE, Wozniak DJ, Mizel SB.

Vaccine. 2009 Nov 12;27(48):6762-9. doi: 10.1016/j.vaccine.2009.08.080. Epub 2009 Sep 8.

PMID:
19744586
10.

Direct stimulation of tlr5+/+ CD11c+ cells is necessary for the adjuvant activity of flagellin.

Bates JT, Uematsu S, Akira S, Mizel SB.

J Immunol. 2009 Jun 15;182(12):7539-47. doi: 10.4049/jimmunol.0804225.

11.

A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.

Weimer ET, Lu H, Kock ND, Wozniak DJ, Mizel SB.

Infect Immun. 2009 Jun;77(6):2356-66. doi: 10.1128/IAI.00054-09. Epub 2009 Apr 6.

12.

Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates.

Mizel SB, Graff AH, Sriranganathan N, Ervin S, Lees CJ, Lively MO, Hantgan RR, Thomas MJ, Wood J, Bell B.

Clin Vaccine Immunol. 2009 Jan;16(1):21-8. doi: 10.1128/CVI.00333-08. Epub 2008 Nov 5.

13.

Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function.

Arimilli S, Johnson JB, Clark KM, Graff AH, Alexander-Miller MA, Mizel SB, Parks GD.

J Virol. 2008 Nov;82(22):10975-85. doi: 10.1128/JVI.01288-08. Epub 2008 Sep 10.

14.

Mucosal adjuvant activity of flagellin in aged mice.

Bates JT, Honko AN, Graff AH, Kock ND, Mizel SB.

Mech Ageing Dev. 2008 May;129(5):271-81. doi: 10.1016/j.mad.2008.01.009. Epub 2008 Feb 17.

15.

Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.

Honko AN, Sriranganathan N, Lees CJ, Mizel SB.

Infect Immun. 2006 Feb;74(2):1113-20.

16.

Effects of flagellin on innate and adaptive immunity.

Honko AN, Mizel SB.

Immunol Res. 2005;33(1):83-101. Review.

PMID:
16120974
17.

Gangliosides inhibit flagellin signaling in the absence of an effect on flagellin binding to toll-like receptor 5.

West AP, Dancho BA, Mizel SB.

J Biol Chem. 2005 Mar 11;280(10):9482-8. Epub 2005 Jan 4.

18.
20.

Identification of a sequence in human toll-like receptor 5 required for the binding of Gram-negative flagellin.

Mizel SB, West AP, Hantgan RR.

J Biol Chem. 2003 Jun 27;278(26):23624-9. Epub 2003 Apr 23.

22.

Activation of interleukin-1 receptor-associated kinase by gram-negative flagellin.

Moors MA, Li L, Mizel SB.

Infect Immun. 2001 Jul;69(7):4424-9.

23.

High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation.

McDermott PF, Ciacci-Woolwine F, Snipes JA, Mizel SB.

Infect Immun. 2000 Oct;68(10):5525-9.

24.
25.
27.

Salmonella flagellin induces tumor necrosis factor alpha in a human promonocytic cell line.

Ciacci-Woolwine F, Blomfield IC, Richardson SH, Mizel SB.

Infect Immun. 1998 Mar;66(3):1127-34.

28.

Salmonellae activate tumor necrosis factor alpha production in a human promonocytic cell line via a released polypeptide.

Ciacci-Woolwine F, Kucera LS, Richardson SH, Iyer NP, Mizel SB.

Infect Immun. 1997 Nov;65(11):4624-33.

30.
31.
32.

Regulation of macrophage activation and human immunodeficiency virus production by invasive Salmonella strains.

Mizel SB, Kucera LS, Richardson SH, Ciacci F, Iyer NP.

Infect Immun. 1995 May;63(5):1820-6.

33.

Interleukin-1 signal transduction.

Brooks JW, Mizel SB.

Eur Cytokine Netw. 1994 Nov-Dec;5(6):547-61. Review. No abstract available.

PMID:
7727688
34.
35.
36.

Activation of AP-1 by IL-1 and phorbol esters in T cells. Role of protein kinase A and protein phosphatases.

Chedid M, Yoza BK, Brooks JW, Mizel SB.

J Immunol. 1991 Aug 1;147(3):867-73.

PMID:
1713607
37.

Involvement of a calpain-like protease in the processing of the murine interleukin 1 alpha precursor.

Carruth LM, Demczuk S, Mizel SB.

J Biol Chem. 1991 Jul 5;266(19):12162-7.

38.

Expression of interleukin-1 alpha and beta genes by human blood polymorphonuclear leukocytes.

Lord PC, Wilmoth LM, Mizel SB, McCall CE.

J Clin Invest. 1991 Apr;87(4):1312-21.

39.

How does interleukin 1 activate cells? Cyclic AMP and interleukin 1 signal transduction.

Mizel SB.

Immunol Today. 1990 Nov;11(11):390-1. No abstract available.

PMID:
1964052
40.
42.

IL-1 secretion by macrophages. Enhancement of IL-1 secretion and processing by calcium ionophores.

Suttles J, Giri JG, Mizel SB.

J Immunol. 1990 Jan 1;144(1):175-82.

PMID:
2104887
43.

The interleukins.

Mizel SB.

FASEB J. 1989 Oct;3(12):2379-88. Review.

PMID:
2676681
45.
47.
48.

Evidence against the existence of a membrane form of murine IL-1 alpha.

Minnich-Carruth LL, Suttles J, Mizel SB.

J Immunol. 1989 Jan 15;142(2):526-30.

PMID:
2783440
49.

Cyclic AMP--an intracellular second messenger for interleukin 1.

Shirakawa F, Yamashita U, Chedid M, Mizel SB.

Proc Natl Acad Sci U S A. 1988 Nov;85(21):8201-5.

50.

Characterization of the human interleukin 1 receptor on human polymorphonuclear leukocytes.

Rhyne JA, Mizel SB, Taylor RG, Chedid M, McCall CE.

Clin Immunol Immunopathol. 1988 Sep;48(3):354-61.

PMID:
2969785

Supplemental Content

Loading ...
Support Center